Wageningen, The Netherlands
January 8, 2007
Keygene N.V. has developed a new mutation screening
technology applicable for efficient screening of mutant
populations (e.g. EMS populations used for Tilling) and to
reveal natural variation. The KeyPoint™ technology is based on
the combination of a DNA pooling strategy with high throughput
sequencing power such as the Roche/454 Life Sciences Genome
Sequencer System (GS system).
Compared with currently available
mutant screening technologies KeyPoint provides additional speed
and accuracy in pointing the exact location of multiple
mutations present in multiple genes in a mutant population in
one sequence run. In addition, the technology directly provides
the sequence information required to establish the nature of the
identified mutations (frame shift, stop codon, amino acid change
or nonsense mutation).
The KeyPointTM technology will be
presented to the genomics community by Keygene N.V. (Dr. Michiel
van Eijk) at the Plant & Animal Genome conference in San Diego
(January 13-17, 2007).
Keygene will offer the KeyPoint
technology to its customers through a service program.
"Our KeyPoint technology overcomes
limitations of current (pre-) screening technologies and is
applicable in any species for which mutant populations are
available", says Michiel van Eijk, manager Upstream Research of
Keygene. "The technology offers a fast and direct track to
identify mutations to be directly used for commercial
applications in breeding programs".
Keygene N.V. is an
internationally operating R&D company with the mission to be the
leading company in developing and applying DNA expertise in the
field of molecular genetics for its shareholder breeding
companies. Keygene has developed a strong proprietary technology
platform based on AFLP®, SNPWaveTM and CRoPSTM. Keygene exploits
its proprietary technologies, databases and know-how through
contract research and products for applications in the Life
Sciences. Keygene has five shareholders consisting of major
vegetable seed companies: De Ruiter Seeds, ENZA Zaden, Rijk
Zwaan, Vilmorin & Cie and Takii & Co. Keygene has around 100
researchers and staff.
The AFLP®, SNPWave™, CRoPS™ and
KeyPoint™ technologies are covered by patents and/or patent
applications of Keygene N.V. AFLP is a registered trademark of
Keygene N.V. Applications for trademark registration for CRoPS,
SNPWave and KeyPoint have been filed by Keygene N.V.